Evidence map›Paper›PMID 24037023›Full record

ArticleBone marrow transplantation2014

The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT.

A Marek, M Stern, Y Chalandon, M Ansari, H Ozsahin, T Güngör, B Gerber, T Kühne, J R Passweg, A Gratwohl and 6 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Immunity to Infections after Haploidentical Hematopoietic Stem Cell Transplantation.Mediterranean journal of hematology and infectious diseases · 2016
    Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

A MarekDivision of Hematology, University Hospital Zürich, Zürich, Switzerland.
M SternDivision of Hematology, Department of Internal Medicine, University Hospital Basel, Basel, Switzerland.
Y ChalandonService of Hematology, Department of Internal Medicine, University Hospital Geneva, Geneva, Switzerland.
M AnsariHematology and Oncology Unit, Department of Pediatrics, University Hospital Geneva, Geneva, Switzerland.
H OzsahinHematology and Oncology Unit, Department of Pediatrics, University Hospital Geneva, Geneva, Switzerland.
T GüngörDivision of Immunology/BMT, Children's Hospital, University of Zürich, Zürich, Switzerland.
B GerberDivision of Hematology, University Hospital Zürich, Zürich, Switzerland.
T KühneDivision of Oncology/Hematology, University Children's Hospital Basel, Basel, Switzerland.
J R Passweg1] Division of Hematology, Department of Internal Medicine, University Hospital Basel, Basel, Switzerland [2] Service of Hematology, Department of Internal Medicine, University Hospital Geneva, Geneva, Switzerland.
A GratwohlDivision of Hematology, Department of Internal Medicine, University Hospital Basel, Basel, Switzerland.
A TichelliDivision of Hematology, Department of Internal Medicine, University Hospital Basel, Basel, Switzerland.
R SegerDivision of Immunology/BMT, Children's Hospital, University of Zürich, Zürich, Switzerland.
U SchanzDivision of Hematology, University Hospital Zürich, Zürich, Switzerland.
J HalterDivision of Hematology, Department of Internal Medicine, University Hospital Basel, Basel, Switzerland.
G StussiDivision of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
Swiss Blood Stem Cell Transplantation

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several T-cell depletion (TCD) techniques are used for haploidentical hematopoietic SCT (HSCT), but direct comparisons are rare. We therefore studied the effect of in vitro TCD with graft engineering (CD34 selection or CD3/CD19 depletion, 74%) or in vivo TCD using alemtuzumab (26%) on outcome, immune reconstitution and infections after haploidentical HSCT. We performed a retrospective multicenter analysis of 72 haploidentical HSCT in Switzerland. Sixty-seven patients (93%) had neutrophil engraftment. The 1-year OS, TRM and relapse incidence were 48 (36-60)%, 20 (11-33)% and 42 (31-57)%, respectively, without differences among the TCD groups. In vivo TCD caused more profound lymphocyte suppression early after HSCT, whereas immune recovery beyond the second month was comparable between the two groups. Despite anti-infective prophylaxis, most patients experienced post-transplant infectious complications (94%). Patients with in vivo TCD had a higher incidence of CMV reactivations (54% vs 28%, P=0.015), but this did not result in a higher TRM. In conclusion, TCD by graft engineering or alemtuzumab are equally effective for haploidentical HSCT.

Indexed as

AdolescentAdsorptionAdultAlemtuzumabAntibodies, Monoclonal, HumanizedAntigens, CD19Antigens, CD34Antineoplastic AgentsCD3 ComplexChildChild, PreschoolFemaleGraft vs Host DiseaseHematologic NeoplasmsHematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationAlemtuzumabAntibodies, Monoclonal, HumanizedAntigens, CD19Antigens, CD34Antineoplastic AgentsCD3 Complex

Identifiers

PMID24037023

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.